Hei reddit, Mainz Biomed (NASDAQ: MYNZ) is mapping out a solid US push for their next-gen colorectal cancer assay. The finance card above shows it at $1.49, down a touch today. eAArly DETECT 2's interim readout hit end-summer 2025, with top-line data due Q4 2025. That'll lock in protocols for ReconAAsense, their pivotal US study kicking off in 2026.

Strong Q4 results could shave timelines, draw partners, and spark reimbursement talks - huge for competing with stool/blood tests. Key watches till year-end: sensitivity/specificity goals, sample size, FDA input. If data shines and prep holds, 2026 flips MYNZ into a US powerhouse. You stacking shares pre-Q4?











  
COOT INDP BE GIG ARQQ SMCI ZCMD ASTL GPUS SOS QCLS AAME DWTX LUD WOK SNAP GOVX RAYA RAPT JNJ MLTX CYCU DRDB GLXY OLB EQX ASBP CRWD CHOW KRMN UNFI SCOR NUVB OVID IBM STKS QUBT BA OTLK SYPR VNRX CYCN EYPT INTJ PLUT CRCL WIMI TSSI CRM SPRC GDEV GOOG AMD AGH ISPC HIMS NBY PMEC ZYBT FBGL BKKT WAB BYRN POAI VFF FGL VOR USAR WNW IRBT APH BETR INVZ AXIL DOMO BREA MFH YDES SNWV PLTS SGLY LGCY DUO DKNG FISI TSLA YCBD APLT UHG DVLT IREN RKLB BCAX AMPY KCHV TLIH XIFR ATMC YGMZ INV IBG REFR CNCK WFC DSS OPEN IVDA LRMR ANGX AMAT SOPH EGG NUWE SOFI FLUX WMT RGTI IOBT GIFT PBFS BANL JAGX DKI HIND MRAM BQ HBNB FBIO PSTV RVSN TAOP HOWL MAPS AREC BYND PHAT CCL TLRY SPRU PTIX RMSG SCYX ANSC VUZI PULM V MSS PATH AIMD AMST BEEM NEOV

MYNZ's US CRC Path: eAArly DETECT 2 Data to Fuel 2026 Breakthrough?